kwic
response
response
right
off
ON
256
1
100
500
strict
ELIZA cgi-bash version rev. 1.91
- Medical English LInking keywords finder for the PubMed Zipped Archive (ELIZA) -
return
kwic search for response out of >500 occurrences
343831 occurrences (No.54 in the rank) during 5 years in the PubMed. [cache]
--- ABSTRACT ---
--- ABSTRACT END ---
[frequency of next (right) word to response]
343831 occurrences (No.54 in the rank) during 5 years in the PubMed. [cache]
| 256) This study focused on tackling this important issue by elucidating the critical role of sterol regulatory element-binding protein 1 (SREBP1) degradation in conferring the response of EGFR mutant NSCLC cells to osimertinib and by validating the strategy via directly targeting SREBP1 for overcoming osimertinib acquired resistance. |
| PMID:34635799 DOI:10.1038/s41388-021-02057-0 |
| 2021 Oncogene |
| * Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib. |
| - Emergence of acquired resistance to osimertinib (AZD9291), the first-approved third-generation EGFR inhibitor that selectively and irreversibly inhibits the activating EGFR mutations and the resistant T790M mutation, is a giant and urgent clinical challenge. Fully understanding the biology underlying the response of EGFR mutant non-small cell lung cancer (NSCLC) to osimertinib is the foundation for development of mechanism-driven strategies to overcome acquired resistance to osimertinib or other third-generation EGFR inhibitors. This study focused on tackling this important issue by elucidating the critical role of sterol regulatory element-binding protein 1 (SREBP1) degradation in conferring the response of EGFR mutant NSCLC cells to osimertinib and by validating the strategy via directly targeting SREBP1 for overcoming osimertinib acquired resistance. Osimertinib facilitated degradation of the mature form of SREBP1 (mSREBP1) in a GSK3/FBXW7-dependent manner and reduced protein levels of its regulated genes in EGFR-mutant NSCLC cells/tumors accompanied with suppression of lipogenesis. Once resistant, EGFR-mutant NSCLC cell lines possessed elevated levels of mSREBP1, which were resistant to osimertinib modulation. Both genetic and pharmacological inhibition of SREBP1 sensitized osimertinib-resistant cells and tumors to osimertinib primarily through enhancing Bim-dependent induction of apoptosis, whereas enforced expression of ectopic SREBP1 in sensitive EGFR-mutant NSCLC cells compromised osimertinib's cell-killing effects. Collectively, we have demonstrated a novel connection between osimertinib and SREBP1 degradation and its impact on the response of EGFR mutant NSCLC cells to osimertinib and suggested an effective strategy for overcoming acquired resistance to osimertinib, and possibly other EGFR inhibitors, via targeting SREBP1. |
[
right
kwic]
(1)170  to |
(11)5 rates |
(21)2 although |
(31)2 profiles |
| (2)56 *null* | (12)5 with |
(22)2 are |
(32)2 regulator |
| (3)27 and |
(13)3 at |
(23)2 bias, |
(33)2 relationship |
| (4)21 of |
(14)3 bias |
(24)2 burden |
(34)2 surface |
| (5)20 in |
(15)3 genes |
(25)2 compared |
(35)2 theory |
| (6)11 was |
(16)3 the |
(26)2 curve |
(36)2 time |
| (7)8 that |
(17)3 through |
(27)2 during |
(37)2 when |
| (8)7 is |
(18)3 were |
(28)2 from |
|
| (9)5 by |
(19)2 (UPR) |
(29)2 observed |
|
| (10)5 rate |
(20)2 across |
(30)2 our |
add keyword
--- WordNet output for response ---